Arctic Bioscience (Hold, TP: NOK15.00) - Set for HeROPA-trial readout
Arctic Bioscience announced that the 6-month primary endpoint readout from the HeROPA trial is expected at end-September/in early October. We see this as a key event for the company and crucial for its plans within the psoriasis segment. After adjusting our total psoriasis market size and our nutraceutical sales estimates, we reiterate our HOLD, but have raised our target price to NOK15 (10).
DNB Markets is the investment banking arm of DNB Bank ASA and is focused primarily on the Nordic region, as well as internationally on niches such as global shipping, energy and related services, and seafood. DNB Markets offers services in FICC, Equities and Investment Banking advisory from offices in Oslo, Stockholm, London, Singapore and New York. Equity research coverage is offered on c250 Nordic companies. DNB was ranked no.2 in Extel Nordic Research 2017. The DNB Markets’ Credit and FICC Macro & FX Research teams are repeatedly highly rated by Prospera Nordic Institutional Investor Surveys.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.